CDK2 and ovarian cancer: Using ovarian cancer as a model system, we have compared directly the acute effect of selective CDK4/6 inhibition (PD0332991 = palbociclib) or CDK2 inhibition (SNS032, dinaciclib), as well as mechanisms of resistance.